X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the X4 Pharmaceuticals First Quarter 2025 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin. Thank you, operator, and good morning, everyone. Presenting on today's call will be X-Force Chief Executive Officer, Dr. Paula Reagan, and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, and we'll be joined by Chief Commercial Officer, Mark Baldry, and Chief Medical Officer, Dr. Christoph Arbit Engels. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including last year's Form 10-K and this past quarter's Form 10-Q, which is expected to be filed after market close today. Please note, that the X4 investor deck was updated this morning on the company website to include slides detailing some of the data analyses mentioned in this morning's press release and on this call today. I'd now like to turn the call over to X4's president and CEO, Dr. Paula Regan. Paula? Thank you, Dan, and thanks to all of you for joining us this morning. The first quarter of 2025 was an extremely productive and value-building period for X4, with clinical trial advancement in chronic neutropenia, continued progress in the commercialization of Zolremdi for WHIM ...